LAS VEGAS, Dec. 28, 2009 (GLOBE NEWSWIRE) -- In the growing category of women's oncological needs, introduction of new technologies are paramount to better care for the patient and for the corporate health of the companies pioneering the innovation. A new RFID Tag device being developed by SenoRx Inc. (Nasdaq:SENO), a company that is exclusively focused on breast cancer intervention, could soon be the next innovative product to come out of their robust R&D pipeline.
For women's health, the device could be extremely important and beneficial. For SenoRx and its shareholders, completion of the product development would be another in a series of achievements by the company and continuing evidence of their ability to capitalize on a broad and innovative pipeline for new products to further strengthen and expand the SenoRx brand -- all while helping doctors treat patients more effectively.
SenoRx recently announced that it was conducting market research for a new RFID tag and accompanying handheld reader which the company believes may be the next generation lesion localization device. The benefits of the device may offer significant improvements in scheduling logistics and workflow between the radiologist and surgeon. Also since the RFID tag is contained inside the patient's breast, there is no protruding wire common in similar procedures today, thus potentially reducing the risk of infection and the urgency to perform the surgical procedure the same day. In the current course of treatment it is imperative that a patient rapidly go from radiologist to surgeon to minimize risk of infection and patient discomfort.
It is a clear market opportunity for SenoRx with over a half million lumpectomies and excisional biopsies each year. But more importantly, successful adaptation of the device would further SenoRx's leadership in women's oncology, adding another innovation to its roster of successes that include achievements in minimally invasive tissue removal technologies and implantables.
SenoRx has a rich history of successful innovative product developments focused on the breast cancer arena, offering health care providers both diagnostic and therapeutic technologies to better detect and treat breast cancer, the second most frequently diagnosed cancer among women. Their current products include EnCor (R), currently the only "open/closed" tissue collection system providing the operator with a clear view of tissue samples through a proprietary transparent collection chamber, and the ability to either open the chamber to examine and remove one or more samples, or to continue uninterrupted collection of multiple samples. In addition, SenoRx has also given health care providers Contura (TM), its Multi-Lumen Radiation Balloon (MLB) catheter, for delivering targeted radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. Earlier this year, SenoRx introduced StarchMark(TM) to its wide array of advanced biopsy site markers, the first and only breast biopsy marker to use starch to help manage and control bleeding in the biopsy cavity.
In addition to the new RFID Tag that is in development, SenoRx has several new product introductions planned for 2010 and beyond. These include a second-generation EnCor system, a Teatherless breast biopsy device and a next-generation radiation therapy product. Now as the company begins its market research for its new RFID Tag device, the health care community and investor base that has seen SENO roll out multiple new product offerings may well have another reason to follow this innovator increasingly established at the crossroads of women's health care and oncology create further shareholder value.
Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. Small Cap Sentinel is property of Integrity Media Inc. (IMI). IMI provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies haven't always approved the statements made in this report. This report is neither a solicitation to buy nor offer to sell securities and is for information purposes only and shouldn't be used as basis for investment decisions. IMI isn't an investment advisor, analyst or licensed broker dealer and this report isn't investment advice. IMI has been paid thirty-thousand dollars by SenoRx for this report and other services to be performed over the remainder of the calendar year. Paid reports constitute a conflict of interest as to IMI's ability to remain objective in communication regarding subject companies.